Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers

Trial Profile

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs Tebipenem pivoxil (Primary)
  • Indications Haemophilus infections; Streptococcal infections; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 27 Sep 2018 According to a Spero Therapeutics media release, company reported positive results from this study.
    • 27 Sep 2018 Results published in the Spero Therapeutics Media Release
    • 25 Sep 2018 According to a Spero Therapeutics media release, data from the trial will be presented at the Infectious Disease Society of America (IDSA) IDWeek 2018 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top